The Veterinary Medicines Regulations 2009

PART 2 Fees relating to marketing authorisations

Fees for specified pharmaceutical applications

7.  The following table sets out the fees relating to a pharmaceutical veterinary medicinal product for—

(a) a national application for a marketing authorisation that is—

(i) a full application under Part 1 of Schedule 1;

(ii) a bibliographic application; or

(iii) an application based on pharmacological equivalence;

(b) an application for a marketing authorisation using the decentralised procedure where the United Kingdom is a concerned member State;

(c) an application for the mutual recognition of a product authorised in another member State.

Menu	Full national application under Part 1 of Schedule 1 (£)	Bibliographic national application (£)	Pharmacologically equivalent national application		Decentralised application where the UK is a concerned member State or recognition of a product authorised in another member State (£)
			Reference product authorised in UK (£)	Reference product not authorised in UK (£)
Base Fee:	950	1,885	1,885	2,410	470
The following fees are in addition to the base fee:
Quality assessment (if quality data are assessed):	3,970	3,365	2, 825	3,620	1, 880
Safety assessment (if safety data are assessed):	3,970	3, 165	1,075	1,380	1,880
Efficacy assessment (if efficacy data are assessed):	3,970	3,165	1,075	1,380	1,880
Ecotoxicology assessment: (if ecotoxicology data are assessed):	670	535	335	430	405
Additional fee if any of the target species is a food-producing animal (not payable if neither safety data nor ecotoxicology data are assessed):	3,905	3,585	2,155	2,760	1,415
Reduced by—
if no safety data are assessed:	2,190	2,190	1,340	1,715	670
if no ecotoxicology data are assessed:	1,035	790	305	390	305
Additional fee for each active ingredient not previously included in a veterinary medicinal product authorised in the United Kingdom—
food-producing animal:	7,465	6,595	5,855	7,495	2,630
non-food-producing animal:	6,525	5,855	5,590	7,155	2,295
Additional fee for each additional pack type:	740	740	605	775	330
Reduced by—
if no quality data are assessed:	365	365	365	465	120
if no safety data are assessed:	185	185	120	155	60
if no efficacy data are assessed:	60	60	60	80	60
if no ecotoxicity data are assessed:	60	60	-	-	60
Additional fee for each additional active ingredient (food-producing animal):	6,465	6,125	4,040	5,165	2,085
Reduced by—
if no quality data are assessed:	1,460	1,460	1,460	1,870	485
if no safety data are assessed:	2,740	2,740	1,645	2,100	850
if no efficacy data are assessed:	915	730	550	700	305
if no ecotoxicity data are assessed:	730	610	-	-	245
Additional fee for each additional active ingredient (non-food-producing animal):	4,310	4,105	3,235	4,135	1,475
Reduced by—
if no quality data are assessed:	1,460	1,460	1,460	1,870	485
if no safety data are assessed:	1,460	1,460	915	1,170	485
if no efficacy data are assessed:	915	730	550	700	305
if no ecotoxicity data are assessed:	60	60	-	-	60
Additional fee if there is more than one target species, for each additional species (food-producing animal):	3,970	3,565	2,425	3,100	1,280
Reduced by—
if no quality data are assessed:	185	185	185	235	60
if no safety data are assessed:	1,460	1,460	915	1,170	485
if no efficacy data are assessed:	1,825	1,460	1,095	1,400	550
if no ecotoxicity data are assessed:	120	120	-	-	60
Additional fee if there is more than one target species, for each additional species (non- food-producing animal):	2,495	2,090	1,550	1,980	805
Reduced by—
if no quality data are assessed:	185	185	185	235	60
if no safety data are assessed:	185	185	120	155	60
if no efficacy data are assessed:	1,825	1,460	1,095	1,400	550
if no ecotoxicity data are assessed:	60	60	-	-	60
Additional fee for each additional recommended route of administration (food-producing animal):	2,695	2,490	1,620	2,070	940
Reduced by—
if no safety data are assessed:	1,460	1,460	915	1,170	485
if no efficacy data are assessed:	915	730	550	700	305
if no ecotoxicity data are assessed:	60	60	-	-	60
Additional fee for each additional recommended route of administration (non- food-producing animal):	1,215	1,010	740	945	405
Reduced by—
if no safety data are assessed:	185	185	120	155	60
if no efficacy data are assessed:	915	730	550	700	305
Simultaneous applications: fee for each additional product in the application:	2,895	2,895	2,895	3,705	1,685

Decentralised pharmaceutical application where the United Kingdom is the reference member State

8.  The fee for a decentralised application for a pharmaceutical product where the United Kingdom is the reference member State is the same as for a national application as set out in the table in paragraph 7, with the addition of the fees in the following table.

Decentralised pharmaceutical application where the United Kingdom is the reference member State

Application	Additional fee for a pharmacologically equivalent product (£)	Additional fee otherwise (£)
Food-producing animal: one member State:	5,230	3,705
Non-food-producing animal: one member State:	3,985	3,220
Each additional member State:	530	530
Simultaneous application: fee for each additional product in the application:
one member State	6,670	6,670
each additional member State	120	120

Application for a marketing authorisation for an immunological product

9.  The fee for a national application for a marketing authorisation relating to an immunological product, a decentralised application where the United Kingdom is the concerned member State or the mutual recognition of a product authorised in another member State is in accordance with the following table.

Fees for specified immunological applications

Menu	National application for a marketing authorisation(£)	Decentralised application where the UK is a concerned member State or recognition of a product authorised in another member State (£)
1. Immunological product other than in paragraph 2: Base fee:	11,775	5,785
The following fees are in addition to the base fee.
Additional fee for each active ingredient not previously included in a veterinary medicinal product authorised in the United Kingdom, and for each new combination of active ingredients:	7,405	2,490
Additional fee for each adjuvant or preservative not previously included in a veterinary medicinal product authorised in the United Kingdom and for each new combination of adjuvants or preservatives:	1,345	675
More than one antigenic component – fee for each additional component:	1,350	405
More than one species – fee for each additional species	5,380	1,615
More than one route of administration – fee for each additional route of administration	5,380	1,615
Simultaneous application - fee for each additional product in the application	2,895	1,685
2. Immunological product that is identical to a product already authorised in the United Kingdom but with a lesser number of antigens and that only contains antigens contained in that product	10,430	5,380

Decentralised immunological application where the United Kingdom is the reference member State

10.  The fee for a decentralised application for a marketing authorisation for an immunological product where the United Kingdom is the reference member State is the same as for a national application set out in the previous table, with the addition of the fees in the following table—

Decentralised immunological application where the United Kingdom is the reference member State

Application	Additional fee (£)
One member State	3,470
Each additional member State	530
Simultaneous applications: fee for each additional product in the application
one member State	6,670
each additional member State	120

Application for a marketing authorisation using identical data

11.  The fee for an application for a marketing authorisation using identical data is in accordance with the following table.

Identical data

Application	Fee (£)
Decentralised application where the United Kingdom is the reference member State—
one member State:	4,165
each additional member State:	530
Any other application	945

Application for an exceptional marketing authorisation (pharmaceutical)

12.  The fee for an application for an exceptional marketing authorisation for a pharmaceutical product is in accordance with the following table.

Fees for an exceptional marketing authorisation for a pharmaceutical product

Menu	Fee (£)
Base Fee:	950
The following fees are in addition to the base fee:
Quality assessment (if quality data are assessed):	3,970
Safety assessment (if safety data are assessed):	3,970
Efficacy assessment (if efficacy data are assessed):	2,455
Ecotoxicology assessment (if ecotoxicology data are assessed):	670
Additional fee if any of the target species is a food-producing animal (not payable if neither safety data nor ecotoxicology data are assessed):	3,905
Additional fee for each active ingredient not previously included in a veterinary medicinal product authorised in the United Kingdom—
food-producing animal:	5,850
non-food-producing animal:	4,910
Additional fee for each additional pack type:	710
Additional fee for each additional active ingredient (food-producing animal):	5,955
Additional fee for each additional active ingredient (non-food-producing animal):	3,800
Additional fee if there is more than one target species, for each additional species (food-producing animal):	2,965
Additional fee if there is more than one target species, for each additional species (non- food-producing animal):	1,485
Additional fee for each additional recommended route of administration (food-producing animal):	2,185
Additional fee for each additional recommended route of administration (non- food-producing animal):	710
Simultaneous applications— fee for each additional product in the application:	2,895

Fees for an application for an exceptional marketing authorisation (immunological)

13.  The fee for an application for an exceptional marketing authorisation for an immunological product is in accordance with the following table.

Fees for an exceptional marketing authorisation for an immunological product

Menu	Fee (£)
Base fee:	10,810
The following fees are in addition to the base fee.
Additional fee for each active ingredient not previously included in a veterinary medicinal product authorised in the United Kingdom, and for each new combination of active ingredients:	5,650
Additional fee for each adjuvant or preservative not previously included in a veterinary medicinal product authorised in the United Kingdom and for each new combination of adjuvants or preservatives:	1,350
More than one antigenic component – fee for each additional component:	1,190
More than one species – fee for each additional species:	4,060
More than one route of administration – fee for each additional route of administration:	4,060
Simultaneous application - fee for each additional product in the application	2,895

Fee for the conversion from an exceptional to a full marketing authorisation

14.  The fee for the conversion of an exceptional marketing authorisation to a full marketing authorisation is the same as the fee for an application for a full marketing authorisation except that, if the application for conversion is made within two years of the grant of the exceptional marketing authorisation, the fee is £5,865.

Application for a marketing authorisation relating to a parallel import

15.  The fee for a marketing authorisation for a parallel import is in accordance with the following table.

Parallel imports

Application	Fee (£)
Application where the imported product has been authorised in accordance with the mutual recognition procedure or decentralised procedure, and the United Kingdom is included in these procedures—
import from one member State:	1,775
each additional member State:	355
Application to add an additional member State after the marketing authorisation has been granted—fee for each member State	455
Any other application—fee for each member State from which the product is imported:	2,130

Application for a variation obtained under a national procedure

16.—(1) — This paragraph applies in relation to an application for a variation to a marketing authorisation obtained under a national procedure.

(2) An applicant must make a separate application for a variation for each change in the marketing authorisation (unless a change is a direct consequence of the first change) and the appropriate fee is payable for each application.

(3) As an exception from sub-paragraph (1), an applicant who applies for more than one variation to the quality data in a marketing authorisation on the same application form may elect to pay a total fee of £4,620; but this sub-paragraph does not apply—

(a) if one or more of the variations relates to a new source of an active substance and the applicant does not submit a Certificate of Suitability issued by the European Pharmacopeia relating to the new source, or

(b) if a significant formulation change is applied for that requires a new assessment of the safety or efficacy of the veterinary medicinal product.

(4) If the variation is one specified as Type 1A in Commission Regulation (EC) No 1084/2003(1), the fee is £455.

(5) If the variation is specified as Type 1B in those Regulations, the fee is £885 except in accordance with the following table.

Reductions to Type 1B fees

Variation	Conditions	Fee (£)
Identical changes to a number of products	All the products are from the same marketing authorisation holder Supporting data are identical All applications are submitted at the same time	First product	885
		Each subsequent product	455

(6) The fee for a variation classified as Type II in Commission Regulation (EC) No 1084/2003 is £2,310 except in the following cases, where the fee is as specified.

Reductions to Type II fees

Change	Conditions	Fee (£)
a) Identical changes to a number of products	All the products are from the same marketing authorisation holder Supporting data are identical All applications are submitted at the same time	First product Each subsequent product	2,310 455
b) Change of distributor	No other aspect of the dossier is changed and the marketing authorisation holder remains the same	885
c) Change of legal entity of marketing authorisation holder	No other aspect of the dossier is changed	885
d) Simple dosage instruction changes intended to remove ambiguity	The change is not as a result of safety concerns No new studies are required to support the change The dosage regime remains the same	885
e) Addition or change to safety warnings	No other aspects of the dossier are changed No safety warnings are removed No new studies are required to support the change and the proposed warnings serve to increase the protection of the user/ environment /target species as appropriate	885
f) Corrections or simple text layout changes to summary of product characteristics and/or product literature. Included in this is the introduction of multilingual labelling	The changes are not a result of safety concerns No new studies are required to support the change and no other aspect of the dossier is changed The legibility of the current English labelling is not compromised The indications and warnings are the same in all languages	885
g) Abbreviated resubmission of a previously refused Type II variation	At the time of refusal of a Type II variation, the Secretary of State has given written permission for resubmission under this category The application has been resubmitted within 3 months of the date the refusal advice was issued	885
h) Submission made following the formal advice of the Secretary of State	The Secretary of State has already assessed the relevant data and formed an opinion on these The change is not required as a result of the holder failing to keep the Part II (quality) data in accord with current practice or in line with current guidelines issued by the Committee for Medicinal Products for Veterinary Use(2)	885
i) Approval of a mock-up for an authorised pack size	The pack size is already authorised No new studies are required to support the change and no other aspect of the dossier is changed	885
j) Changes to the summary of product characteristics and product literature of a marketing authorisation for parallel import as a direct consequence of the approval of a variation to the summary of product characteristics and product literature for the United Kingdom authorised product	The only changes to the summary of product characteristics and product literature are those required to bring the marketing authorisation for parallel import back in direct line with those of the United Kingdom authorised product	885
k) Changes to details of the marketing authorisation holder’s pharmacovigilance system	No other changes to the dossier	885

Application for a variation to a marketing authorisation obtained through mutual recognition or decentralised procedures: fees until 1st January 2010

17.—(1) This paragraph applies until 1st January 2010.

(2) It applies in relation to an application for a variation to a marketing authorisation obtained through mutual recognition or decentralised procedures.

(3) In this paragraph the types of variation are those specified in Commission Regulation (EC) 1084/2003.

(4) An applicant must make a separate application for a variation for each change in the marketing authorisation (unless a change is a direct consequence of the first change).

(5) The fee is in accordance with the following table.

Variations

Type of variation	UK is the reference member State (£)	UK is a concerned member State (£)
Type II variation:	5,200	3,120
If a marketing authorisation holder applies for a Type II variation for a number of marketing authorisations, and—
all the applications have identical supporting data
all the changes are identical
all the applications are submitted at the same time
the fee payable is—
for the first variation:	5,200	3,120
for each subsequent variation:	685	455
If a marketing authorisation holder—
applies for a Type II variation to correct the summary of product characteristics or product literature or where variations are required for simple text layout changes
the change is not a result of safety concerns
no new studies are required to support the change
no other aspects of the dossier are changed
the fee payable is:	1,325	885
Changes to details of the marketing authorisation holder’s pharmacovigilance system (no other changes to the dossier)	1,325	885
Type 1A variation:	685	455
Type 1B variation:	1,325	885
If a marketing authorisation holder applies for a Type 1B variation for a number of marketing authorisations, and—
all the applications have identical supporting data
all the changes are identical
all the applications are submitted at the same time
the fee payable is—
for the first variation	1,325	885
for each subsequent variation	685	455

Application for a variation to a marketing authorisation obtained through mutual recognition or decentralised procedures: fees from 1st January 2010

18.—(1) This paragraph applies from 1st January 2010.

(2) It applies in relation to an application for a variation to a marketing authorisation obtained through mutual recognition or decentralised procedures.

(3) In this paragraph the types of variation are those specified in Commission Regulation (EC) 1234/2008 (concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products(3)).

(4) An applicant must make a separate application for a variation for each change in the marketing authorisation (unless a change is a direct consequence of the first change) except where the variations are grouped in accordance with Article 7 of Commission Regulation (EC) No 1234/2008 (“grouped variations”).

(5) In this paragraph “worksharing” means the procedure set out in Article 20 of Commission Regulation (EC) No 1234/2008.

(6) The fee for any kind of variation where the Agency co-ordinates worksharing is £455 for each marketing authorisation.

(7) In any other case the fee is in accordance with the following table.

Variations

Type of variation	UK is the reference member State (£)	UK is a concerned member State (£)
(a) A co-reference member State is a member State appointed to assist the reference member State in the assessment of specific marketing authorisations.
Type II variation
Application for a grouped variation:	12,060	6,240
Any other application:	6,030	3,120
Type II variation using the worksharing procedure
Application for a grouped variation—
Base fee (including the first nine changes):	13,265	5,620 (6,745 where the United Kingdom is co-reference member State(a))
For the tenth and each subsequent ten changes:	4,500	4,500
Any other application:	6,630	2,810
Type IB variations
Application for a grouped variation:	2,650	1,770
Any other application:	1,325	885
Type IB variations using the worksharing procedure
Application for a grouped variation—
Base fee (including the first nine changes):	2,915	1,590 (1,910 where the United Kingdom is co-reference member State(a))
For the tenth and each subsequent ten changes:	4,500	4,500
Any other application:	1,325	885
Type IA variation
Application for a grouped variation—
Base fee (including the first nine changes):	1,325	885
For the tenth and each subsequent ten changes:	4,500	4,500
Notification under Article 8 of Commission Regulation (EC) No 1234/2008:	1,325	885
Any other application	685	455
Type 1A variation using the worksharing procedure
Application for a grouped variation—
Base fee (including the first nine changes):	1,460	820
For the tenth and each subsequent ten changes:	4,500	4,500

Application for an extension to a marketing authorisation

19.  The fee for an application for an extension to a marketing authorisation is in accordance with the following table.

Extension to a marketing authorisation

Extension	Fee if the marketing authorisation was obtained using a national procedure (£)	Fee for a decentralised application where the United Kingdom is a concerned member State or the mutual recognition of an extension authorised in another member State (£)
Change of strength or potency or the addition of a new strength or potency	6,670	3,300
Change of pharmaceutical form or the addition of a new pharmaceutical form	8,415	3,835
Change of route of administration, or the addition of a new one, of—
an immunological product, or a pharmaceutical product for a non food-producing animal:	5,390	2,895
a pharmaceutical product for a food-producing animal:	7,135	3,430
Change or addition of target species	9,620	4,245
Change of active substance	8,415	3,835
Other	8,415	3,835
Simultaneous application: fee for each additional product in the application	2,895	1,685

Decentralised application for an extension where the United Kingdom is the reference member State

20.  The fee for a decentralised application for an extension where the United Kingdom is the reference member State is the same as for a national application as set out in the table in paragraph 19, with the addition of the fees in the following table.

Decentralised application for an extension where the United Kingdom is the reference member State

Application	Additional fee (£)
Pharmaceutical product for a food-producing animal – one member State:	3,705
Pharmaceutical product for a non-food-producing animal – one member State:	3,220
Immunological product – one member State:	3,460
Each additional member State:	530
Simultaneous application: fee for each additional product in the application:
one member State	6,670
each additional member State	115

Provision of information relating to the recognition of a United Kingdom marketing authorisation

21.—(1) Where an application is made for the Secretary of State to provide information to other member States to enable them to recognise a marketing authorisation already granted by the United Kingdom the following fees are payable.

(2) Where a valid application to provide information to another member State is received within six months of the original grant of the marketing authorisation, or where the Secretary of State has already provided the information to a member State, and a further valid application is made to provide the information to an additional member State within six months of the date the last information was provided, the fees are—

Type of application	Fee for a pharmacologically equivalent product (£)(a)	Fee (other products) (£)
(a) This fee is payable if the application for the marketing authorisation was on the basis that the product was pharmacologically equivalent to another veterinary medicinal product.
Pharmaceutical product for a food-producing animal – one member State:	3,940	2,440
Pharmaceutical product for a non-food-producing animal – one member State:	2,645	1,895
Immunological product – one member State:	2,130	2,130
Each additional member State:	535	535

(3) In any other case the fees are—

Type of application	Fee for a pharmacologically equivalent product (£)(a)	Fee (other products) (£)
(a) See footnote for previous table.
Pharmaceutical product for a food-producing animal – one member State:	12,015	10,515
Pharmaceutical product for a non-food-producing animal – one member State:	8,115	7,365
Immunological product – one member State:	8,940	8,940
Each additional member State:	535	535

(4) In the case of simultaneous applications, the above fees are payable for each additional product in the application for one member State, with a fee of £115 for each additional product for each additional member State.

Application for the renewal of a national marketing authorisation

22.—(1) The fee for an application for the renewal of a marketing authorisation originally granted on or after 30th October 2005 is £1,360.

(2) In the case of a marketing authorisation originally granted before 30th October 2005 —

(a) if it is the first time the marketing authorisation has been renewed the fee is £1,360 and otherwise £305;

(b) if further assessment of post authorisation commitments is required the fee is £660.

(3) The fee for the first reassessment of an exceptional marketing authorisation is £305, and the fee for each subsequent reassessment is £1,360.

Application for the renewal of a marketing authorisation obtained through mutual recognition or the decentralised procedure

23.  The fee for an application for the renewal of a marketing authorisation obtained through mutual recognition or the decentralised procedure is —

(a) £1,835 if the United Kingdom is the reference member State, and

(b) £1,225 if the United Kingdom is a concerned member State.

Registration of a homeopathic remedy

24.  The fee for an application for the registration of a homeopathic remedy is in accordance with the following table.

Fee for the registration of a homeopathic remedy

Type of application	Fee(£)
If all stocks and the formulation have already been assessed by the Secretary of State—
not more than five stocks:	160
more than five stocks:	375
If either all the stocks have already been assessed by the Secretary of State but there is a new formulation, or if the formulation has already been assessed by the Secretary of State but one or more of the stocks have not been already assessed—
not more than five stocks:	455
more than five stocks:	665
If the formulation and at least one of the stocks has not already been assessed by the Secretary of State—
not more than five stocks:	760
more than five stocks:	985
If the product is already authorised for human use in the United Kingdom, or for human or veterinary use in the United Kingdom or in another member State—
not more than five stocks:	160
more than five stocks:	375

Annual fees for marketing authorisations

25.—(1) Within 30 days of receiving a written demand from the Secretary of State, a holder of a marketing authorisation must provide the Secretary of State with a statement of turnover for the previous calendar year; and, if specified in the demand, an audit certificate relating to the turnover.

(2) When providing the statement of turnover the holder must pay an annual fee, rounded up to the next £10, of—

where T is the annual turnover in the previous calendar year and n is the number of active marketing authorisations held at any time during the previous calendar year.

(3) In the case of an authorisation holder with a turnover relating to all marketing authorisations held of less than £230,000, the amount, rounded up to the next £10, is—

where T is the annual turnover in the previous calendar year and n is the number of active marketing authorisations held at any time during the previous calendar year.

(4) In this paragraph—

“turnover” means the sales value at manufacturers’ prices of all authorised veterinary medicinal products sold or supplied in the United Kingdom;

“manufacturers’ prices” means the prices charged (excluding value added tax) for authorised products by manufacturers to wholesalers, except to the extent that—

(a)

the products are supplied by manufacturers direct to retailers, in which case it means the prices charged for the products by the manufacturers to the retailers reduced by such sum as, in the opinion of the Secretary of State, represents the difference between the prices paid by the retailers and those which could be expected to be charged by the manufacturers to wholesalers according to the practice prevailing during the period in question with regard to such products;

(b)

a marketing authorisation holder sells or supplies products that the marketing authorisation holder has neither manufactured nor obtained from the manufacturer, in which case it means the prices paid by the marketing authorisation holder for those products.

Auditor’s certificate

26.—(1) If the Secretary of State required an audit certificate when the demand for the statement of turnover was sent out, and the holder of the marketing authorisation has not provided it within 30 days, an additional fee is payable for that year of £11,200 plus an additional £2,245 in respect of each marketing authorisation held.

(2) If the Secretary of State is not satisfied that the audit certificate provides sufficient assurance that the figures fairly present the financial records of the company, the Secretary of State may require the marketing authorisation holder to produce within 30 days a further certificate and specify what further assurances are needed; and if these are not provided within those 30 days the additional fee specified in sub-paragraph (1) is payable.

(3) Nothing in this paragraph limits the powers of an inspector to examine financial records.

Late payment of annual fees

27.—(1) Any person who fails to pay the annual fee for a marketing authorisation within 30 days from and including the date of the demand must pay an additional fee, rounded up to the nearest £10, of—

(a) where payment is received after 30 but before 60 days have expired from and including the due date, 1% of the annual fee;

(b) where payment is received after 60 but before 90 days have expired from and including the due date, 2% of the annual fee; and

(c) where payment has not been received after the expiry of 90 days, 5% of the annual fee.

(2) Where a marketing authorisation holder has not provided the Secretary of State with a statement of annual turnover so that the annual fee cannot be determined before the due date, the holder may make a payment of an amount on account of the annual fee, in which case the additional fee is calculated on the difference between the amount paid on account and the actual amount due.

(1)

On 1st January 2010 this Regulation is superseded by Commission Regulation (EC) No 1234/2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products (OJ No L 334, 12.12.2008, p. 7) but for the purposes of variations to marketing authorisations granted under the national procedure the classifications in Commission Regulation (EC) No 1084/2003 continue to be used.

(2)

The Committee was established by Article 30 of Regulation (EC) No 762/2004 of the European Parliament `and of the Council laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ No L136, 30.4.2004, p. 1).

(3)

OJ No L334, 12.12.2008, p. 7. This Regulation supersedes Regulation (EC) No 1084/2003 on 1st January 2010.